Novo Nordisk
NVO
558 hedge funds and large institutions have $7.89B invested in Novo Nordisk in 2018 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 162 increasing their positions, 199 reducing their positions, and 38 closing their positions.
263% more call options, than puts
Call options by funds: $78.9M | Put options by funds: $21.7M
61% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 38
4% more funds holding
Funds holding: 537 → 558 (+21)
4% more capital invested
Capital invested by funds: $7.57B → $7.89B (+$329M)
0.36% more ownership
Funds ownership: 17.17% → 17.53% (+0.36%)
19% less repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 199
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$73.1M |
| 2 |
Two Sigma Investments
New York
|
+$27.2M |
| 3 |
Renaissance Technologies
New York
|
+$25.6M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$22.3M |
| 5 |
Millennium Management
New York
|
+$21.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$28.5M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$28.2M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$21.5M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$19.8M |
| 5 |
Jane Street
New York
|
-$14.9M |
NVO Hedge Fund Activity: Q3 2018 in Review
558 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q3 2018, worth a combined $7.89B — up 4.3% from $7.57B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new NVO positions and 38 closed out — a net gain of 23 holders — while 162 added to existing stakes and 199 trimmed.
The largest buyer was AllianceBernstein, opening a new position worth an estimated $73.1M. The largest seller was D.E. Shaw & Co, cutting an estimated $28.5M.
- 558 institutional investors held Novo Nordisk (NVO) as of Q3 2018, up from 537 in Q2 2018.
- Funds reported $7.89B of Novo Nordisk stock for Q3 2018, up 4.3% quarter-over-quarter.
- 61 funds opened new Novo Nordisk positions in Q3 2018 and 38 closed out, a net change of +23 holders.
- The largest Novo Nordisk buyer in Q3 2018 was AllianceBernstein, an estimated $73.1M added.
- The largest Novo Nordisk seller in Q3 2018 was D.E. Shaw & Co, an estimated $28.5M sold.
Based on aggregated 13F filings for Q3 2018.